Wolf Haldenstein Appointed Lead Counsel in Consolidated Securities Class Action against Curaleaf

Wolf Haldenstein was appointed lead counsel in a consolidated securities class action against Massachusetts-based Curaleaf Holdings, Inc . (“Curaleaf” or the “Company”). The allegations against Curaleaf include the failure to disclose it was illegally marketing CBD products as new drugs without approval from the U.S. Food and Drug Administration (“FDA”). Investors learned about Curaleaf’s alleged illegal marketing after the FDA issued a warning letter to the Company in July 2019 about its advertising practices which appeared to take liberties regarding the health benefits of CBD. The complaint further alleges that  Curaleaf’s share price fell by more than 7% thereafter.